

To: CN=Katherine A Armington/OU=AM/O=LLY@Lilly; CN=Robert W Baker/OU=AM/O=LLY@Lilly; CN=Patrizia Cavazzoni/OU=AM/O=LLY@Lilly; CN=Re Jana F Garon/OU=AM/O=LLY@Lilly; CN=Cassandra Mehlman/OU=AM/O=LLY@Lilly; CN=Margaret O Sowell/OU=AM/O=LLY@Lilly; CN=Virginia Stauffer/OU=AM/O=LLY@Lilly

CC: CN=Molly A Bodenschatz/OU=AM/O=LLY@Lilly; CN=Michael D Griffith/OU=AM/O=LLY@Lilly; CN=Bruce Kinon/OU=AM/O=LLY@Lilly; CN=Eric L Prouty/OU=AM/O=LLY@Lilly; CN=John R Richards/OU=AM/O=LLY@Lilly

Date: 11/20/2001 03:15:29 PM

From: CN=Elvis A Rivera/OU=AM/O=LLY

Subject: US Psych Congres: Metabolic Issues

Attachments: Remake slides.ppt



Remake slides.ppt

Hi Team,

Attached are 3 slides that were presented this past week at US Psych Congress. Three separate symposiums that focused on metabolic issues.

1. Recognizing and Managing Medical Complications of Atypical Antipsychotics:
Sponsored by AstraZeneca
Speaker: Henry Nasrallah, MD
2. Atypical Antipsychotics: A Metabolic Risk Assessment
Sponsored by Janssen
Speaker: John Newcomer, MD
3. Redefining Optimal patient management in Schizophrenia
Sponsored by Pfizer
Speaker: John Newcomer, MD

All three programs highlighted slides 1 & 2 (Publish case reports:summary). The AstraZeneca program added a slide titled, "suggestions for management in clinical practice" (slide 3).

We need help in verifying the facts of slide 1 & 2 (both the same slide with different references) and provide an adequate rebuttal (slide w/speaker notes).

We are requesting your help so that we can provide our national speakers, "answers that matter" in several upcoming formats:

Page: 1 of 2

December 7, 2001: Jay Fawver will be sharing a meeting with John Newcomer. The meeting will be taking place in Pittsburgh and will allow each speaker to talk for one hour (Jay will follow Newcomer).

January 24-26, 2002: Diabetes SCC presenting to 200 top key thought leaders.

Again, Thank you for your help!!!

Molly Bodenschatz
Elvis Rivera
Zyprexa Brand Team